MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414763 | Name: Parapenzolate Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Parapenzolate Free Base is a safe and effective anticholinergic drug possessing antisecretory and antimotility properties and prolonged duration of action. Clinical investigation has shown that after an oral dose of the drug there was inhibition of both basal and histamine-stimulated acid outputs.

Chemical Structure

Parapenzolate Free Base
Parapenzolate Free Base
CAS#15394-61-3 (free base)

Theoretical Analysis

MedKoo Cat#: 414763

Name: Parapenzolate Free Base

CAS#: 15394-61-3 (free base)

Chemical Formula: C21H27NO4

Exact Mass: 357.1940

Molecular Weight: 357.45

Elemental Analysis: C, 70.56; H, 7.61; N, 3.92; O, 17.90

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
15394-61-3 (free base); 5634-41-3 (Br)
Synonym
Parapenzolate Free Base
IUPAC/Chemical Name
4-Hydroxy-1,1-dimethylpiperidinium benzilate
InChi Key
ZZTQQNKHMGWDAE-UHFFFAOYSA-M
InChi Code
InChI=1S/C14H12O3.C7H16NO/c15-13(16)14(17,11-7-3-1-4-8-11)12-9-5-2-6-10-12;1-8(2)5-3-7(9)4-6-8/h1-10,17H,(H,15,16);7,9H,3-6H2,1-2H3/q;+1/p-1
SMILES Code
C[N+]1(C)CCC(O)CC1.OC(C2=CC=CC=C2)(C3=CC=CC=C3)C([O-])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 357.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Boisson J. Les indications du parapenzolate en pathologie digestive [Indications of parapenzolate in digestive pathology]. Therapeutique. 1970 May;46(5):561-5. French. PMID: 5430230. 2: Schilliro R, Coste. Expérimentation clinique du Parapenzolate injectable en urologie [Clinical experimentation with injectable Parapenzolate in urology]. J Urol Nephrol (Paris). 1972 Oct-Nov;78(10):950-2. French. PMID: 4659954. 3: Boisson J. Etude de la durée d'action d'un nouveau corps: le bromure de parapenzolate par une méthode originale [Study on the duration of action of a new substance, parapenzolate bromide, by an original method]. Therapeutique. 1969 Nov;45(9):894-6. French. PMID: 5365418. 4: Messi G, Cupula CA, Morel CJ. Experiencia clínica con el empleo de bromuro de parapenzolato y diclorhidrato de flufenazina en el tratamiento de úlceras gástricas y duodenales [Clinical experience with the use of parapenzolate bromide and fluphenazine in the treatment of duodenal and gastric ulcers]. Prensa Med Argent. 1971;58(13):653-7. Spanish. PMID: 5566937. 5: Paris J, Robelet A, Salembier Y, Wantiez M. Actions de bromure de parapenzolate sur la motricité des voies biliaires [Action of parapenzolate bromide on biliary tract motility]. Therapie. 1968 May-Jun;23(3):609-18. French. PMID: 5740625. 6: Fung WP. Effect of parapenzolate bromide (Relanol) on the gastric acid secretion of patients with peptic ulceration. Aust N Z J Med. 1972 Feb;2(1):37-8. doi: 10.1111/j.1445-5994.1972.tb03905.x. PMID: 4502716. 7: Mazure PA, Schraier M, Lew V. Acción de un nuevo anticolinérgico. Bromuro de parapenzolato sobre la secreción gástrica basal posthistamina en dosis máxima [Effect of a new anticholinergic. Parapenzolate bromide on gastric basal post- histamine secretion in large doses]. Prensa Med Argent. 1968 Jun 7;55(15):694-7. Spanish. PMID: 4185879. 8: Truchot R, Brette R. A propos d'un nouvel anticholinergique de synthèse, le parapenzolate bromide (S.C.H. 3444): modalités d'actions biologique et thérapeutique [A new synthesized anticholinergic, parapenzolate bromide (S.C.H. 3444): mode of biologic and therapeutic action]. Therapeutique. 1969 Dec;45(10):1017-20. French. PMID: 5386098. 9: Bielanów T, Gabryś M, Szacki J, Bartoszewicz T. Ocena skojarzonego leczenia niewydolności cieśniowo-szyjkowej [Evaluation of combined treatment of cervix incompetence]. Wiad Lek. 1985 Apr 15;38(8):556-60. Polish. PMID: 3892925.